tirzepatide vomiting How should I manage a patient who vomits after the 10 mg weekly injection, given they previously tolerated up to 7.5 mg? Retatrutide for weight loss: Study

Folic acid in obstetric practice: a review

Unlike traditional clomiphene, which contains both enclomiphene and zuclomiphene (an estrogenic isomer), enclomiphene consists only of the active component responsible for stimulating testosterone production without increasing estrogenic side effects

This hormone plays a vital role in regulating key metabolic processes, making Semaglutide highly effective for managing both diabetes and weight loss

One must raise awareness, promote safe treatments, and protect patients from risks

The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes